Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (**Currently Amended**) A method for identifying agents which may be potentially pro-apoptotic or anti-apoptotic, comprising:

   A) providing a reaction mixture including complexes of ~~BAK and/or~~ M11L ~~proteins~~;

   B) contacting the reaction mixture with one or more test agents; and,

   C) determining if the test agents possess ~~test agent possesses~~ at least one of the following abilities:

      1) binding to the complex;

      2) increasing or decreasing the steady state level of the complex;

      3) affecting an enzymatic activity of the complex; and,

      4) affecting a subcellular localization of the complex;

   wherein the test agents are potentially pro-apoptotic or anti-apoptotic if the test agents possess at least one of the abilities of C).

2. (**Currently Amended**) The method of claim 1, wherein the agents are ~~agent is~~ polypeptides, nucleic acids, carbohydrates, small organic molecules, or natural product extract libraries.

3. (**Currently Amended**) The method of claim 2, wherein the agents are ~~agent is~~ from natural product extract libraries isolated form animals, plants, fungus, or microbes.

4. (**Original**) The method of claim 1, wherein the method is repeated for a variegated library of at least 10 different members.

5. (**Original**) The method of claim 4, wherein the method is repeated for a variegated library of at least 100 different members.

6. (**Original**) The method of claim 5, wherein the method is repeated for a variegated library of at least 1,000 different members.

7. (**Original**) The method of claim 6, wherein the method is repeated for a variegated library of at least 10,000 different members.

8. **(Currently Amended)** The method of claim 1, further comprising:

D) determining, if the test agents ~~agent~~, which possess ~~possesses~~ at least one of the abilities of C), are ~~is~~ pro-apoptotic or anti-apoptotic.

9. **(Original)** The method of 8, wherein step D) is carried out in vivo or in whole cells.

10. **(Original)** The method of claim 1, wherein the reaction mixture is a cell-free system.

11. **(Original)** The method of claim 10, wherein the cell-free system comprises reconstituted protein mixture of semi-purified proteins.

12. **(Original)** The method of claim 10, wherein the cell-free system comprises reconstituted protein mixture of highly-purified proteins substantially lacking impurity.

13. **(Currently Amended)** The method of claim 10, wherein at least one member of said complexes of ~~BAK and/or~~ M11L ~~proteins~~, or the test agents, are ~~agent, is~~ immobilized on a solid support.

14. **(Original)** The method of claim 13, wherein the immobilization is effected by chemical cross-linking, by indirect conjugating via an intermediate molecule, or by direct coating of said solid support.

15. **(Original)** The method of claim 14, wherein the intermediate molecule is an antibody or biotin.

16. **(Original)** The method of claim 13, wherein the solid support is microtiter plates, microarrays, test tubes, microcentrifuge tubes, or solid matrices.

17. **(Currently Amended)** The method of claim 13, wherein said at least one member of said complexes of ~~BAK and/or~~ M11L ~~proteins~~, or said test agents are ~~is a~~ fusion proteins adapted to bind said solid support.

18. **(Currently Amended)** The method of claim 10, wherein at least one member of said complexes of ~~BAK and/or~~ M11L ~~proteins~~, or the test agents, are ~~, is~~ labeled.

19. **(Original)** The method of claim 18, wherein the label is a radioisotope, a fluorescent label/tag, an epitope tag, or an enzyme.

20. **(Original)** The method of claim 10, wherein the cell-free system is generated from lysates, each containing one or more of the relevant polypeptides, which lysates are

mixed appropriately or spiked, wherein no single lysate contains all the component necessary for generating said cell-free system.

21. (**Original**) The method of claim 20, wherein one or more of said relevant polypeptides is recombinantly generated.

22. (**Original**) The method of claim 20, wherein said lysates derive from one or more cell types selected from bacteria cells, yeast cells, worm cells, insect cells, amphibian cells, plant cells, or mammalian cells.

23. (**Original**) The method of claim 1 or 8, wherein the reaction mixture is a cell.

24. (**Original**) The method of claim 23, wherein the method is carried out using a yeast two-hybrid assay or reverse yeast two-hybrid assay.

25. (**Currently Amended**) The method of claim 23 [[24]], wherein the method employs an Interaction Trap System (ITS) or reverse ITS.

26-37. (**Canceled**)

38. (**New**) The method of claim 1, wherein said complexes of M11L comprises BAX.